Syvak L. Prognostic Value of clinical-hematological and immunological characteristics of patients with non-Hodgkin's malignant lymphomas from mature (peripheral) B-cells

The complex of diagnostic, clinical-hematological, immunological, cytomorphological prognostic criteria was formed taking into account the immunophenotypical features of tumor cells. It complements the International prognostic index and will promote the enhancement of treatment efficacy of non-Hodgkin's malignant lymphoma patients. It was observed the marked influence of clinical-hematological characteristics (age, disease stage, anemia) as well as peculiarities of malignant cell immunophenotype (increase of number of CD38+ cells in bone marrow) on overall survival of B-NHL patients. It was proven that deficiency of HLA-DR+ (< 20%) in peripheral blood of B-NHL patients is unfavourable prognostic factor (risk of lethality is increased almost by a factor of 2). It was found that deficiency of CD5+ cells in bone marrow (< 20%) in B-NHL patients is accompanied by an increase of lethality by a factor of 1.8. It was defined that low level of apoptosis in tumor lymphoid cells (up to 4%) in peripheral blood and both Epstein-Barr virus and hepatitis C virus seropositivity are also unfavourable prognosis for disease outcome in B-HNL patients. It was proven that the treatment of B-NHL patients with low grade of malignancy was more efficiently than such patients with high grade malignancy. It was shown that complete remission in B-NHL patients resulted in the reduction of probability of lethality by a factor of 2.5. The algorithm of prognosis of complete remission in B-NHL patients was worked out and substantiated scientifically